QuidelOrtho Earnings Call: Growth, Margins And Risks

Quidelortho Corporation ((QDEL)) has held its Q4 earnings call. Read on for the main highlights of the call.

QuidelOrtho Corporation’s latest earnings call struck a cautiously optimistic tone as management balanced solid execution with clear near-term challenges. Executives highlighted that they met full-year revenue guidance, expanded EBITDA margins, and advanced their product pipeline, yet they were candid about headwinds from weaker respiratory testing, gross margin pressure, leverage, and a large noncash goodwill impairment.

Revenue Growth Anchored by Non-Respiratory Strength

QuidelOrtho reported full-year 2025 revenue of $2.73 billion and fourth-quarter revenue of $724 million, up 2% year over year on a reported basis. Excluding COVID and Donor Screening, Q4 growth accelerated to 7% and full-year non-respiratory revenue (excluding Donor Screening) increased 5%, underscoring the diversification of the business away from pandemic-driven volumes.

Labs Segment Drives Durable, Recurring Growth

The Labs business, now the core of the company, represented 55% of total revenue and delivered 7% growth in Q4 and 6% for the full year. Management emphasized the strength of its clinical chemistry offerings and a recurring revenue model that provides visibility and resilience, positioning Labs as the primary engine for more stable and predictable growth.

Margin Expansion Supported by Cost Savings

Profitability improved meaningfully as QuidelOrtho achieved $140 million in cost savings and expanded full-year adjusted EBITDA margin to 22%, an increase of 240 basis points. Operating expenses fell 5% for the year, helping lift margins into the low‑20% range and signaling that the integration and efficiency programs are starting to deliver structural benefits.

R&D Progress and Product Pipeline Milestones

The company showcased a healthy innovation engine with key regulatory and product milestones in 2025, including FDA clearances for a high-sensitivity troponin assay on VITROS and the ID MTS Direct Antiglobulin Test Card on Vision, plus the launch of Results Manager middleware. Looking ahead to 2026, management flagged upcoming launches like the VITROS 450 outside the U.S., partner immunoassay platforms with about 25 assays, and the LEX molecular platform now in the final stages of FDA review.

Segment and Regional Bright Spots

Operationally, several businesses and geographies outperformed, with Triage point-of-care revenue up 16% in Q4 and 7% for the year, and Immunohematology growing 3% for 2025. Regionally, Latin America led with 17% Q4 and 18% full-year growth, while Japan and Asia Pacific rose 4% in Q4 and 6% for the year, and EMEA posted 4% annual growth alongside more than 900 basis points of adjusted EBITDA margin expansion.

Respiratory Declines and Seasonal Volatility

The main drag on results came from respiratory testing, where revenue fell 14% in Q4 and 20% for the full year as COVID testing volumes normalised sharply from pandemic peaks. Management noted that this respiratory variability, including flu season dynamics, is the primary driver of the wide revenue and earnings range for 2026, leaving some uncertainty around short-term performance.

Free Cash Flow Below Target Amid Timing Issues

Free cash flow was a weak spot, with recurring full-year free cash flow of $100 million, equal to 17% of adjusted EBITDA and below the company’s 25% conversion target. Q4 was particularly affected by $15–20 million of ERP-related accounts receivable issues and roughly $20 million of late-quarter sales that pushed cash collection into January 2026, depressing quarterly free cash flow conversion to about 17%.

Leverage Remains Elevated Versus Goals

On the balance sheet, net debt to adjusted EBITDA stood at 4.2 times at year-end 2025, above management’s desired range and highlighting leverage as a near-term overhang. While guidance calls for improvement to around 3.8 times by the end of 2026, investors will likely watch closely to see if execution on margin expansion and cash generation is sufficient to accelerate deleveraging toward the longer-term 2.5–3.5 times target.

Q4 Gross Margin Pressure Despite Full-Year Gain

Fourth-quarter profitability showed some strain as adjusted gross margin slipped to 44.9% from 46.8% a year earlier, a 190-basis-point decline driven by tariffs, increased instrument placements, and an unfavorable product mix. For the full year, however, adjusted gross margin still improved modestly to 47.4%, up 40 basis points, suggesting the underlying margin structure is firming even as quarterly volatility persists.

Noncash Goodwill Impairment Weighs on GAAP Results

Reported GAAP earnings were significantly affected by a $701 million noncash goodwill impairment recorded in the third quarter of 2025, tied to post-pandemic market valuation shifts. While management stressed that this charge does not impact cash flow or day-to-day operations, it is material for reported results and underscores how the company’s acquisition accounting is being recalibrated to the new testing demand reality.

China Policy Risk Adds an External Overhang

Management also flagged policy uncertainty in China, where a potential nationalized volume-based procurement program for dry chemistry test strips remains under discussion. If implemented and if these products are included, the company estimates a potential revenue impact of roughly 0.5% to 1% of total sales, creating an additional macro-driven downside risk that investors will need to monitor.

Forward Guidance Signals Margin Upside but Ongoing Volatility

For 2026, QuidelOrtho guided revenue to a range of $2.7–$2.9 billion with a similar quarterly pattern to 2025 and neutral foreign exchange, expecting Labs to grow mid-single digits, Immunohematology low single digits, and Point-of-Care roughly flat at the midpoint, with COVID revenue essentially flat around $8 million. Adjusted EBITDA is forecast at $630–$670 million, implying a 23.3% margin and about 130 basis points of improvement, while free cash flow is projected at $120–$160 million after $50–$60 million of one-time cash uses, and net leverage is targeted to decline to about 3.8 times by year-end alongside flat gross margins, $250 million of depreciation, and $150–$170 million in capital spending.

QuidelOrtho’s earnings call painted a company transitioning from pandemic-driven swings to a more stable, lab-centric growth model, but still working through volatility in respiratory testing and balance sheet leverage. Investors will weigh the clear progress on margins, cost savings, and product innovation against softer free cash flow, elevated debt, and external risks, with 2026 set up as a proving year for the company’s margin and deleveraging ambitions.